JNJ-79635322 Dose Escalation Study in Multiple Myeloma Shows Promising Combinations
The study aims to establish recommended Phase 2 doses for JNJ-79635322 in combination with daratumumab and other agents.
Company
Pharmaceutical intelligence for JNJ-79635322 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.